Benchmark lowered the firm’s price target on Clene to $5 from $7 and keeps a Buy rating on the shares after updating the firm’s target to reflect the plans to pursue accelerated approval for ALS and the postponement of the PD program as well as the recently completed secondary stock offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLNN:
- Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks — Here’s Why You Might Want to Steer Toward Them Too
- Clene announces publication of Phase 2 CNM-Au8 clinical data
- Clene price target lowered to $5.00 from $6.00 at Canaccord
- Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million
- Clene price target lowered to $7 from $15 at H.C. Wainwright